Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06897670

Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study

The purpose of this research is to measure brain activity in individuals with mood disorders and memory problems using a simple, safe, and noninvasive method called functional near-infrared spectroscopy (fNIRS). By comparing brain activity across different groups and relating it to symptom severity, this study aims to improve our understanding of how these conditions affect the brain.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic

Rochester, Minnesota, 55905, United States

Location status: Recruiting

Location contact

Maria I. Lapid, M.D.

PRINCIPAL_INVESTIGATOR

Paul H. Min, Ph.D.

PRINCIPAL_INVESTIGATOR

Sarah M. Williams

CONTACT

507-422-2972

About this study

This study will examine cerebral hemodynamic patterns in individuals with mood disorders (major depressive disorder and bipolar disorder) and cognitive disorders (mild cognitive impairment) using functional near-infrared spectroscopy (fNIRS). The primary goal is to compare hemodynamic patterns between these groups, while the secondary goal is to explore correlations between these patterns and symptom severity based on standardized clinical assessments. Additionally, electrophysiological data, including photoplethysmography (PPG) and electrocardiogram (ECG), will be analyzed to investigate autonomic nervous system activity and its relationship with cerebral hemodynamics.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

General Inclusion Criteria (across all diagnostic groups):

  • 18 years and older
  • Ability to provide written informed consent
  • Adequate cognitive and language abilities to understand and complete study tasks, including clinical assessments and fNIRS procedures
  • Confirmed clinical diagnosis of major depressive disorder, bipolar disorder, or mild cognitive impairment (MCI)
  • Stable psychiatric or cognitive condition, without acute episodes requiring immediate intervention

Specific Inclusion Criteria (for diagnostic groups):

  • Healthy control

o No past or current psychiatric or cognitive disorder

  • Major depressive disorder (MDD):
  • Diagnosis of major depressive disorder, confirmed through clinical evaluation.
  • No history of bipolar disorder or psychotic symptoms.
  • Bipolar disorder:

o Diagnosis of bipolar disorder I or II, confirmed through clinical evaluation.

  • Mild Cognitive Impairment (MCI):
  • Pre-existing clinical diagnosis of mild cognitive impairment, supported by neuropsychological testing and/or MRI, PET scan data.
  • No history of major psychiatric disorders, such as major depression, bipolar disorder or schizophrenia.

Exclusion criteria

General Exclusion Criteria (across all diagnostic groups):

  • Active primary psychotic or substance use disorders (except nicotine dependence) within the past year
  • Any severe or unstable medical condition that could interfere with participation or data collection
  • Any active neurological condition (including seizure disorder, traumatic brain injury, stroke) that could affect cognitive functioning or brain imaging results
  • Inability to comply with study procedures, including cognitive testing, fNIRS assessment, or other assessments required by the protocol
  • Pregnant women will be excluded due to potential physiological changes that could affect study outcomes

Specific Exclusion Criteria (for diagnostic groups):

  • Healthy control

o Any past or current psychiatric or cognitive disorder

  • Major depressive disorder (MDD):
  • Diagnosis of bipolar disorder or schizophrenia.
  • Brain stimulation therapy within the past 3 months.
  • Bipolar disorder:

o Diagnosis of schizophrenia or schizoaffective disorder.

  • Mild Cognitive Impairment (MCI):
  • Diagnosis of dementia.
  • Significant cognitive impairment preventing understanding or completion of study tasks.

Treatment and study plan

Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.

Other

Functional near-infrared spectroscopy (fNIRS) transcutaneously measures changes in oxyhemoglobin in the prefrontal cortex using light detection. It is designed to measure variations in cerebral hemodynamics on a real-time basis by radiating a near light beam, at two wavelengths of 780nm and 850nm of laser, into the cerebral cortex.

Participants will undergo a one-time functional near-infrared spectroscopy (fNIRS) procedure to measure cerebral hemodynamic patterns.

  • Resting-State Measurement: 5-10 min resting-state scans.
  • Task-Based Measurement: Participants will be shown an instruction video. Participants will complete a Verbal Fluency Task (VFT) during the fNIRS scan (15-20 min).
  • During the fNIRS scan, optional basic vital signs will be measured using respiratory belts, photoplethysmography (PPG), and electrocardiogram (ECG).
  • Each participant will complete 3 sets of resting-state and task-based measurements.

Total estimated time for fNIRS assessment: 45-60 min.

Primary outcomes

  1. Changes in oxyhemoglobin

    Time frame: Baseline, 60 minutes

    Changes in oxyhemoglobin will be measured with a functional near-infrared spectroscopy (fNIRS) device by radiating a near light beam, at two wavelengths of 780nm and 850nm of laser, into the cerebral cortex. Oxyhemoglobin results are reported as a percentage of oxygen-bound hemoglobin compared to the total hemoglobin in the blood.

Secondary outcomes

  1. Hamilton Depression Rating Scale (HAM-D)

    Time frame: Baseline

    A clinician-administered tool revaluating depression severity. The 17-item version assesses symptoms such as depressed mood, insomnia, and somatic complaints. Each item is scored on a 3- or 5-point scale, resulting in total scores that range from 0 to 52, with scores of 0-7 considered normal, 8-16 indicating mild depression, 17-23 moderate depression, and 24 or greater severe depression.

  2. Young Mania Rating Scale (YMRS)

    Time frame: Baseline

    A clinician-rated scale administered to measure the severity of manic symptoms in participants diagnosed with bipolar disorder (during manic or hypomanic episodes). It includes 11 items assessing areas such as elevated mood, irritability, and hyperactivity. Each item is scored on a scale of 0 to 4 or 0 to 8, with total scores ranging from 0 to 60. Severity thresholds include no significant symptoms (≤12), mild mania (13-20), moderate mania (21-35), and severe mania (>35).

  3. Clinical Global Impression-Bipolar (CGI-BP)

    Time frame: Baseline

    A clinician-rated measure that provides a global assessment of illness severity, improvement, and therapeutic response in individuals with bipolar disorder. It includes separate ratings for mania, depression, and overall illness on a 7-point scale, where 1 indicates "normal, not at all ill" and 7 indicates "among the most severely ill."

  4. Mini-Mental State Examination (MMSE)

    Time frame: Baseline

    The Mini-Mental State Examination is used to assess domains such as orientation, attention, memory, language, and visuospatial skills. It has a maximum score of 30, with lower scores indicating greater cognitive impairment. Scores are typically categorized as no cognitive impairment (24-30), mild cognitive impairment (18-23), and severe cognitive impairment (0-17).

  5. Patient Health Questionnaire-9 (PHQ-9)

    Time frame: Baseline

    The PHQ-9 is a self-report questionnaire used to measure the severity of depressive symptoms over the past two weeks. This questionnaire is used in our clinical practice and will be collected from patient only if not already completed. It consists of nine items, each scored on a scale from 0 ("Not at all") to 3 ("Nearly every day"), with total scores ranging from 0 to 27. Higher scores indicate greater symptom severity, categorized as minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19), and severe depression (20-27).

  6. Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Battery

    Time frame: Baseline

    The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) is a standardized cognitive assessment tool designed to evaluate cognitive decline, particularly in Alzheimer's disease (AD) and mild cognitive impairment (MCI). It includes measures of verbal fluency, word list learning, delayed recall, recognition memory, constructional praxis, and global cognition. The battery incorporates a 15-item abbreviation of the Boston Naming Task (J2) and a slightly modified version of the MMSE that does not use serial 7s (J3).

Study contacts

Contact information is provided by the study sponsor or research team.

Sarah M. Williams

CONTACT

[email protected]

507-422-2972

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Mar 27, 2025
Registry last updated
Apr 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.